Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study

The Lancet

Volumn 381, Issue 9865, 2013, Pages 468-475

  Marcellin, Patrick ^a   Gane, Edward ^b   Buti, Maria ^c   Afdhal, Nezam ^d   Sievert, William ^e   Jacobson, Ira M ^f   Washington, Mary Kay ^g   Germanidis, George ^h   Flaherty, John F ⁱ   Schall, Raul Aguilar ⁱ   Bornstein, Jeffrey D ⁱ   Kitrinos, Kathryn M ⁱ   Subramanian, G Mani ⁱ   McHutchison, John G ⁱ   Heathcote, E Jenny ^j  

^a BEAUJON HOSPITAL   (France)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MONASH MEDICAL CENTRE   (Australia)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h AHEPA UNIVERSITY HOSPITAL   (Greece)

ⁱ GILEAD SCIENCES   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FACE SPASM; FEMALE; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; ISHAK SCORING SYSTEM; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OPEN STUDY; OSTEOPENIA; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; UTERINE CERVIX CANCER; VIROLOGY; VIRUS LOAD;

EID: 84873726484     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61425-1     Document Type: Article

References (34)

1. CJ Chen, HI Yang, J Su et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
2. UH Iloeje, HI Yang, J Su et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678 686
3. UH Iloeje, HI Yang, CL Jen et al. Risk and predictors of mortality associated with chronic hepatitis B infection Clin Gastroenterol Hepatol 5 2007 921 931
4. AS Lok Chronic hepatitis B N Engl J Med 346 2002 1682 1683
5. HB El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
6. JL Dienstag, RD Goldin, EJ Heathcote et al. Histological outcome during long-term lamivudine therapy Gastroenterology 124 2003 105 117
7. YF Liaw, JJ Sung, WC Chow et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
8. SJ Hadziyannis, NC Tassopoulos, EJ Heathcote et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743 1751
9. J-F Dufour, R DeLellis, MM Kaplan Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment Dig Dis Sci 43 1998 2573 2576
10. V Mallet, H Gilgenkrantz, J Serpaggi et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C Ann Intern Med 149 2008 399 403
11. T Poynard, J McHutchison, M Manns et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
12. P Hammel, A Couvelard, D O'Toole et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct N Engl J Med 344 2001 418 423
13. N Berhe, B Myrvang, SG Gundersen Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia Am J Trop Med Hyg 78 2008 228 234
14. L Falize, A Guillygomarc'h, M Perrin et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases Hepatology 44 2006 472 477
15. SJ Hadziyannis, NC Tassopoulos, EJ Heathcote et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
16. P Marcellin, TT Chang, SG Lim et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816
17. P Marcellin, TT Chang, SG Lim et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B Hepatology 48 2008 750 758
18. ER Schiff, SS Lee, YC Chao et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B Clin Gastroenterol Hepatol 9 2011 274 276
19. TT Chang, YF Liaw, SS Wu et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
20. HJ Yuan, MF Yuen, WD Ka-Ho et al. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B J Viral Hepatol 12 2005 373 379
21. CJ Chen, UH Iloeje, HI Yang Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma Curr Hepat Rep 6 2007 9 16
22. R Moucari, A Korevaar, O Lada et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study J Hepatol 50 2009 1084 1092
23. CJ Chen, HI Yang, UH Iloeje Hepatitis B virus DNA levels and outcomes in chronic hepatitis B Hepatology 49 2009 S72 S84
24. Viread (tenofovir disoproxil fumarate) tablets: US prescribing information August 2012 Gilead Sciences Foster City, CA (package insert).
25. P Marcellin, EJ Heathcote, M Buti et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
26. EJ Heathcote, P Marcellin, M Buti et al. Three year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
27. RG Knodell, KG Ishak, WC Black et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 1981 431 435
28. K Ishak, A Baptista, L Bianchi et al. Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696 699
29. Y Zhu, M Curtis, K Borroto-Esoda et al. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays J Virol Methods 173 2011 340 346
30. DS Manning, NH Afdhal Diagnosis and quantitation of fibrosis Gastroenterology 134 2008 1670 1681
31. P Bedrossa, D Dargere, V Paradis Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 38 2003 1449 1457
32. RA Standish, E Cholongitas, A Dhillon et al. An appraisal of the histopathological assessment of liver fibrosis Gut 55 2006 569 578
33. ER Kallwitz, J Layden-Almer, M Dhamija et al. Ethnicity and body mass index are associated with hepatitis C presentation and progression Clin Gastroenterol Hepatol 8 2010 72 78
34. A Berzigotti, G Garcia-Tsao, J Bosch et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis Hepatology 54 2011 555 561